- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04727853
Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)
January 26, 2021 updated by: CSPC Ouyi Pharmaceutical Co., Ltd.
A Multicenter, Open-label, Single-arm Phase 2 Study of Irinotecan Liposome Injection in Patients With Small Cell Lung Cancer (SCLC) Who Have Progressed After Platinum-based First-line Therapy
This study is a multicenter, open-label, single-arm phase 2 study of irinotecan liposome injection in patients with small cell lung cancer (SCLC) who have progressed after platinum-based first-line therapy.
Subjects will receive irinotecan liposome injection until progression or unacceptable toxicity.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Patients with small cell lung cancer who have progressed after platinum-based first-line therapy will be enrolled in this study.
Patients will receive irinotecan liposome injection at 70 mg/m^2 intravenously, over 90 min on Days 1 of every 14-day cycle until progression or unacceptable toxicity.
Imaging assessments will be conducted every three cycles to evaluate the preliminary efficacy of irinotecan liposome injection as second-line regimen in patients with SCLC.
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xuekun Yao, Director
- Phone Number: +8631169085937
- Email: yaoxuekun@mail.ecspc.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years of age. Males or females.
- Histopathologically or cytologically confirmed small cell lung cancer.
- At least one measurable lesion as defined by RECIST V1.1 guidelines. A previously irradiated lesion may be counted as a measurable lesion only if there is a clear sign of progression since the irradiation.
- Must have recurrence or progression after platinum-based, first-line chemotherapy or chemoradiation therapy for the treatment of SCLC.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy >3 months.
- Recovered from the effects of any prior chemotherapy, surgery, radiotherapy or other anti-neoplastic therapy (recovered to no more than Grade 1 of CTCAE 5.0 criteria or baseline, with the exception of alopecia or other toxicity without safety concerns by the investigators' judgment).
- Patient should not receive blood transfusion or supportive care (eg. EPO, G-CSF or others) within 14 days before the initiate dose, and laboratory test should meet the following criteria: neutrophile count (ANC) ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥90 g/L or ≥5.6 mmol/L, serum creatinine ≤1.5×ULN and creatinine clearance rate ≥30 mL/min, total bilirubin ≤1×ULN, AST and ALT ≤2.5×ULN (for patients with liver metastasis: ≤5×ULN)
- Female or male patient of childbearing age must agree to take effective contraception for the duration of treatment plus six months post-treatment completion; female patient must have a negative serum pregnancy test within 7 days before enrollment and must not be lactating female.
- Able to understand and provide an informed consent.
Exclusion Criteria:
- Patients with large cell neuroendocrine lung carcinoma or combined small cell lung carcinoma.
- Patients with history of immunotherapy-induced colitis or pneumonia, confirmed by clinical assessment and/or biopsy.
- Patients with central Nervous System (CNS) metastasis meet any of the following criteria: a) Patient who have developed new or progressive brain metastasis following cranial radiation; b) Patients with the symptomatic Central Nervous System (CNS) metastasis who have used cortisol, radiotherapy, dehydration drugs, etc. to control symptoms in the past two weeks; c) Patients with carcinomatous meningitis; d) Patients with brain stem (midbrain, pons, medulla oblongata) or spinal cord metastasis.
- Uncontrolled third lacunar effusion, not suitable for enrollment by investigator's assessment.
- Previous malignancies in the past five years (except for basal cell carcinoma, squamous cell carcinoma, superficial bladder carcinoma, local prostate carcinoma, carcinoma in situ of cervical, or of others that have been radically resected and have not recurred).
- Patients who have received any of the following treatments, a) Patients who have received prior topoisomerase I inhibitor treatment, including irinotecan or other investigational agents; b) Patients who have used any antibody-drug conjugates or molecular targeted preparation alone or in combination setting; c) Patients who have received more than one line of immunotherapy (immunotherapy in first-line as single or combination is permitted).
- Concomitant use of strong CYP3A4 inducers within 2 weeks or strong CYP3A4 inhibitors or strong UGT1A1 inhibitors within 1 week of the first dose of the study drug.
- Patients who have received any chemotherapy, biological therapy, endocrinotherapy, immunotherapy or investigational therapy within 4 weeks (5 half-lives of the agent, whichever is longer) of the first dose of the study drug, or local palliative radiotherapy or Chinese herbal medicine with anti-tumor indications within 2 weeks of the first dose of the study drug.
- Any major surgery or severe trauma within 4 weeks of the first dose, not including biopsy.
- Severe cardiovascular disease within 6 months prior to enrollment.
- Severe pulmonary disease within 6 months prior to enrolment, such as interstitial pneumonia, pulmonary fibrosis, radiation induced pneumonitis requiring steroid therapy, and other moderate and severe lung diseases which affect lung function.
- Uncontrolled active bleeding or known hemorrhagic constitution.
- Any active infection, in the investigator's opinion, would increase the risk or have an influence on the result of the study, such as acute bacterial infection, tuberculosis, active hepatitis B/C, or HIV infection.
- Known hypersensitivity to any of the components of irinotecan liposome injection, or other liposomal products.
- Clinically significant gastrointestinal disorder, including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > grade 1.
- History of explicit neurological or psychiatric disorders, including epilepsy or dementia.
- Pregnant or lactating female.
- Patient is not suitable for the study in the investigator's opinion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: irinotecan liposome injection
Patients will receive irinotecan liposome injection at 70 mg/m^2 intravenously, over 90 min on Days 1 of every 14-day cycle.
|
Drug: irinotecan liposome injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: From date of first dose until the date of first documented progression, assessed up to 24 months
|
ORR was defined as the proportion of patients who achieved partial response or complete response according to RECIST V1.1 guidelines.
|
From date of first dose until the date of first documented progression, assessed up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
from date of the first dose to date of the first documented disease progression (PD) per RECIST v1.1 or death due to any cause, whichever occurs first.
|
From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
Overall survival (OS)
Time Frame: From date of first dose until the date of death from any cause , assessed up to 24 months
|
from date of the first dose to date of death from any cause
|
From date of first dose until the date of death from any cause , assessed up to 24 months
|
Proportion of Patients with Symptom Improvement
Time Frame: date of the first dose to 30 days after permanent treatment termination
|
Patient-reported EORTC-QLQ symptom scales
|
date of the first dose to 30 days after permanent treatment termination
|
Incidence of treatment-emergent adverse events (AEs), serious adverse events (SAEs) and laboratory abnormalities
Time Frame: date of the first dose to 30 days after permanent treatment termination
|
Incidence of AE, SAE and laboratory abnormalities
|
date of the first dose to 30 days after permanent treatment termination
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK parameters-Cmax
Time Frame: Cycle 1(each cycle is 14 days)
|
Cmax of total, encapsuled and free irinotecan
|
Cycle 1(each cycle is 14 days)
|
PK parameters-AUC
Time Frame: Cycle 1(each cycle is 14 days)
|
AUClast, AUCinf of total, encapsuled and free irinotecan
|
Cycle 1(each cycle is 14 days)
|
PK parameters-others
Time Frame: Cycle 1(each cycle is 14 days)
|
tmax, tlast, t1/2 of total, encapsuled and free irinotecan
|
Cycle 1(each cycle is 14 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yin Cheng, Professor, Jilin Provincial Tumor Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2021
Primary Completion (Anticipated)
June 1, 2022
Study Completion (Anticipated)
June 1, 2022
Study Registration Dates
First Submitted
January 18, 2021
First Submitted That Met QC Criteria
January 26, 2021
First Posted (Actual)
January 27, 2021
Study Record Updates
Last Update Posted (Actual)
January 27, 2021
Last Update Submitted That Met QC Criteria
January 26, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Irinotecan
Other Study ID Numbers
- HE072-CSP-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Cancer (SCLC)
-
AstraZenecaCompletedRefractory Solid Tumours | Relapsed Small Cell Lung Cancer (SCLC)United States, Canada
-
Genentech, Inc.Flatiron Health, Inc.; Foundation Medicine, Inc.CompletedNon-Small Cell Lung Cancer (NSCLC) | Small-Cell Lung Cancer (SCLC)United States
-
Kyowa Kirin Korea Co., Ltd.TerminatedPhase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma | Phase 2 Portion : Small Cell Lung Cancer(SCLC)Korea, Republic of
-
Stanford UniversityTerminatedLung Cancer | Mesothelioma | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC)United States
-
Joel NealNektar TherapeuticsCompletedTumors Metastatic to Brain | Stage IV Non-small Cell Lung Cancer (NSCLC) | Recurrent Non-small Cell Lung Cancer (NSCLC) | Extensive-stage Small Cell Lung Cancer (SCLC) | Recurrent Small Cell Lung Cancer (SCLC) | Metastatic Breast Cancer (mBC)United States
-
Stanford UniversityThe American Association of Physicists in MedicineTerminatedPancreatic Cancer | Lung Cancer | Liver Cancer | Hepatobiliary Cancers | Hepatobiliary Cancers Liver | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC) | Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma) | Hepatobiliary Cancers Gallbladder | Hepatobiliary Cancers...United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedSCLC | Small-cell Lung Cancer | Small Cell Lung Cancer Limited StageUnited States
-
Bristol-Myers SquibbCompletedLung Cancer | Non-small Cell Lung Cancer NSCLC | Small Cell Lung Cancer SCLCChina
-
Haibo ZhangRecruitingSmall Cell Lung Cancer (SCLC)China
-
Giuseppe GiacconeMemorial Sloan Kettering Cancer Center; Vanderbilt UniversityTerminatedSmall Cell Lung Cancer ( SCLC )United States
Clinical Trials on irinotecan liposome injection
-
Fudan UniversityNot yet recruitingSmall Cell Lung Cancer RecurrentChina
-
Luye Pharma Group Ltd.CompletedAdvanced Solid TumorChina
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingAdvanced Breast Cancer
-
Luye Pharma Group Ltd.RecruitingRelapsed Small Cell Lung CancerChina
-
Yakult Honsha Co., LTDCompleted
-
Luye Pharma Group Ltd.CompletedSmall Cell Lung CancerChina
-
Baohui HanNot yet recruitingExtensive-stage Small-cell Lung CancerChina
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology Consortium; The V Foundation for Cancer ResearchCompletedDiffuse Intrinsic Pontine GliomaUnited States
-
Peking University People's HospitalPeking University Shougang Hospital; Shandong Cancer Hospital and InstituteRecruiting
-
IpsenCompletedSmall Cell Lung CancerSpain, United States, France, Taiwan, Korea, Republic of, Germany, China, Belgium, Italy, Brazil, Ukraine, Australia, Russian Federation, Serbia, Poland, Hungary, Turkey, Romania